Jason Rodencal

Jason Rodencal

Auto-generated profile, based on publicly available information

Jason Rodencal

Department of Radiation Oncology, New York University Grossman School of Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
ATAmy Tarangelo
Amy Tarangelo
JRJason Rodencal
Jason Rodencal
JKJoon Tae Kim
Joon Tae Kim
LMLeslie Magtanong
Leslie Magtanong
JLJonathan Z Long
Jonathan Z Long
SDScott J Dixon
Scott J Dixon
Nucleotide synthesis is a metabolically demanding process essential for DNA replication and other processes in the cell. Several anticancer drugs that inhibit nucleotide metabolism induce apoptosis. How inhibition of nucleotide metabolism impacts non-apoptotic cell death is less clear. Here, we report that inhibition of nucleotide metabolism by the p53 pathway is sufficient to suppress the non-apoptotic cell death process of ferroptosis. Mechanistically, stabilization of wild-type p53 and induction of the p53 target gene CDKN1A (p21) leads to decreased expression of the ribonucleotide reductase (RNR) subunits RRM1 and RRM2. RNR is the rate-limiting enzyme of de novo nucleotide synthesis that reduces ribonucleotides to deoxyribonucleotides in a glutathione-dependent manner. Direct inhibition of RNR results in conservation of intracellular glutathione, limiting the accumulation of toxic lipid peroxides and preventing the onset of ferroptosis in response to cystine deprivation. These results support a mechanism linking p53-dependent regulation of nucleotide metabolism to non-apoptotic cell death.

11 June 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
HSH. Broder Schmidt
H. Broder Schmidt
ZJZane A. Jaafar
Zane A. Jaafar
JRJason J. Rodencal
Jason J. Rodencal
MLManuel D. Leonetti
Manuel D. Leonetti
SDScott J. Dixon
Scott J. Dixon
OBOnn Brandman
Onn Brandman
Platinum (Pt) compounds such as oxaliplatin are amongst the most commonly prescribed anti-cancer drugs. Despite their considerable clinical impact, the molecular basis of platinum cytotoxicity and cancer specificity remain unclear. Here, we show that oxaliplatin, a backbone for the treatment of colorectal cancer, causes liquid-liquid demixing of nucleoli at clinically-relevant concentrations by interfering with the interaction networks that organize nucleoli. This biophysical defect leads to cell cycle arrest, impaired rRNA processing and shutdown of PolI-mediated transcription, ultimately resulting in cell death. We propose that the mechanism of action of oxaliplatin provides a blueprint for the therapeutic targeting of the increasing number of cellular processes being linked to biomolecular condensates.

23 September 2026 in Nature
Verified
Journal Article
Open access
PDF file
KGKoelina Ganguly
Koelina Ganguly
KYKeisuke Yamamoto
Keisuke Yamamoto
JRJason Rodencal
Jason Rodencal
JEJoel Encarnacion-Rosado
Joel Encarnacion-Rosado
ASAlbert S. W. Sohn
Albert S. W. Sohn
AKAlec C. Kimmelman
Alec C. Kimmelman
The liver is the primary site of metastasis in pancreatic ductal adenocarcinoma (PDAC), and liver metastases are a major cause of mortality1,2. Nutrient availability in the metastatic niche influences colonization efficiency; however, the metabolic heterogeneity of disseminated tumour cells can also reshape the local microenvironment3,4,5. Loss of phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in de novo serine biosynthesis, is observed in nearly 40% of PDACs, and renders these cells dependent on exogenous serine (exSer)6. Although a neuron–tumour metabolic cross-talk supports exSer-dependent PDAC cells at the primary site6, it remains unclear how these cells adapt to the metastatic liver niche. Here we show that exSer-dependent PDAC cells reprogram neighbouring hepatocytes through a CXCL5–CXCR2 axis. Activation of CXCR2 in hepatocytes promotes PI3K–AKT signalling, leading to the sequestration of FOXO3A in the cytoplasm and derepression of PHGDH transcription, thereby enhancing serine production in hepatocytes. This hepatocyte-derived serine supports the outgrowth of exSer-dependent PDAC liver metastases. Accordingly, genetic or pharmacological inhibition of individual nodes within the CXCL5–CXCR2–PI3K–AKT–FOXO3A axis, or hepatocyte-specific deletion of Phgdh or Cxcr2, markedly reduces the liver-metastasis burden in mice and prolongs survival, particularly when dietary serine is restricted. Our findings reveal a cancer cell–hepatocyte metabolic cross-talk and identify therapeutic targets for exSer-dependent PDAC liver metastases.